Familial hypercholesterolemia, is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases.
Plasma from FH patients under hypolipidemic therapy and patients under combined long-term LDL apheresis/hypolipidemic therapy were analyzed in our study. We measured a profile of 184 cardiovascular diesase associated proteins using a proximity extension assay.